Revolo Biotherapeutics Presents New Data on ‘1805 at the American College of Rheumatology Convergence 2023 Annual Conference

– New preclinical data further elucidate ‘1805’s mechanism of action in rheumatoid arthritis (RA) –

NEW ORLEANS and CAMBRIDGE, UK, November 7, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that new preclinical data on ‘1805 will be presented via two posters at the American College of Rheumatology Convergence 2023 Annual Conference, which is being held November 10–15 at the San Diego Convention Center in San Diego, CA.

“These preclinical data provide further insights into ‘1805’s differentiated mechanism of action,” said Jonathan Rigby, Revolo’s Chief Executive Officer. “While current RA treatments can in part ameliorate joint destruction, they are limited in the ability to prevent osteoclast-induced bone destruction. These results highlight the capacity of ‘1805 to ‘reset’ a number of metabolic pathways involved in bone resorption, thus addressing the progressive bone and joint destruction that is a hallmark symptom of RA. In addition, ‘1805 normalizes the expression of genes abnormally activated in cells from RA patients, such as those associated with inflammation. Altogether, the data support the clinical potential of ‘1805 and its further clinical evaluation. We look forward to initiating the Phase 2b clinical trial in the future.”

The principal investigator of the preclinical translational studies, Carl Goodyear, Professor of Translational Immunology at the University of Glasgow, UK, said “The insights we have generated from this work, emphasize how powerful it is to harness physiological pathways aimed at regulating the immune system. Not only can ‘1805 fundamentally alter cell fate decisions within the innate immune compartment, but it has a unique ability to modulate cells from individuals whose compartment has been perturbed by systemic inflammation. We now need to take these studies to the next step and clearly demonstrate ‘1805’s clinical potential.”

Poster details:

Title: Biologic IRL201805 Drives Differential Cell-contact and Metabolism Transcriptional Profiles in Monocytes from RA Patients Compared to Healthy Donors

Presenter:  Yuriko Yamamura, Research Associate (Immunology & Infection), University of Glasgow
Abstract #:  2149
Date/Time:  November 14, 2023, 9:00 a.m. to 11:00 a.m. PT
Session:  Poster Session C
Presentation highlights:

  • Preclinical and clinical studies to date have demonstrated that ‘1805 interacts directly with monocytes, cells which play a key role in the initiation of inflammation and bone erosion in RA patients.
  • Gene expression data from RA-derived monocytes and those from healthy donors indicate that ‘1805 upregulates the expression of genes that are downregulated in RA while simultaneously downregulating the expression of genes that are upregulated in RA, such as those involved in inflammatory pathways.
  • The effect of ‘1805 is selective towards “diseased” monocytes, as large gene expression changes were not observed in monocytes from healthy donors.

Title:   Novel Biologic IRL201805 Inhibits Osteoclastogenesis in Monocytic Cells from RA Patients

Presenter:  Yuriko Yamamura, Research Associate (Immunology & Infection), University of Glasgow
Abstract #:  2150
Date/Time:  November 14, 2023, 9:00 a.m. to 11:00 a.m. PT
Session:  Poster Session C
Presentation highlights:

  • In RA patients, osteoclasts derived from CD14+CD monocytes (pre-osteoclasts) are associated with a risk of progressive bone and joint destruction, which fundamentally impacts quality of life and often requires subsequent orthopedic surgery.
  • Data from this study suggest that ‘1805 inhibits osteoclast differentiation and activation via modulation of the RANK/RANKL signaling pathway, a key pathway that regulates osteoclast maturation.
  • Evaluation of gene expression showed that exposure of pre-osteoclasts to ‘1805 influenced the expression of multiple other genes involved in osteoclast differentiation.  
  • Notably, ‘1805 influenced metabolic pathways critical for bone resorption, such as V-ATPases. This is particularly relevant, as antiresorptive drugs that inhibit V-ATPase activity have become an area of therapeutic development.

For more information, or to register for the conference: https://rheumatology.org/annual-meeting

About ‘1805
‘1805 is a modified analogue of the endogenous immune-regulatory binding immunoglobulin protein (BiP), a key player in immune function that resets the immune system for long-term disease remission. Its mechanism of action creates vast optionality across multiple indications and routes of administration.

About Revolo Biotherapeutics
Revolo Biotherapeutics is developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, without the immune system suppression seen with current therapies. Its two drug candidates, ‘1805 and ‘1104, a protein and a peptide respectively, reset the immune system to prevent the chronic pro-inflammatory immune response that results in autoimmune or allergic disease. ‘1104 is a peptide derived from a natural immune-regulatory protein and has recently completed two Phase 2a clinical trials for patients with eosinophilic esophagitis (EoE) and allergic disease. The disease-agnostic mechanism of action of Revolo Biotherapeutic’s assets provides a potential platform for the development of treatments for multiple autoimmune and allergic diseases.

For further information, please visit www.revolobio.com.

Company Contact
Marylyn Rigby, VP Investor Relations & Marketing

Media Contact
Monica Rouco Molina, Ph.D.
LifeSci Communications

Scroll to Top

David Southwell


In addition to his role as Chairman of Revolo, David Southwell serves on the Board of Directors for Rocket Pharmaceuticals and PTC Therapeutics. David is the former CEO of TScan Therapeutics. Before that, he served as President and CEO of Inotek Pharmaceuticals until its merger with Rocket Pharmaceuticals in 2018. David has held other senior leadership roles and Board of Director positions at companies including Human Genome Sciences, Sepracor, Spero Therapeutics, inVentiv Health, and THL Credit.

Kari Brown, M.D.

Executive Vice President, Clinical Development, Operations and Strategy

Kari Brown, a board-certified allergist and immunologist, brings 10 years of experience in clinical treatment deployment, development and strategy to Revolo. In her various roles, Kari has played an integral part in advancing pipelines across allergy and immunology disease indications.

Femi Oluboyede

Vice President, Technical Operations, CMC

Femi Oluboyede has over 20 years of experience within the bio-pharma industry, with a proven track record of achieving strategic corporate objectives. Through his roles, Femi has excelled in fostering alignment across functional teams, including Process Development, Tech-transfers, cGMP Manufacturing in Biologics, Small molecules, Proteins and Synthetic Peptides. He has succeeded in delivering investigational products and providing support across different phases of clinical trials.

Tunde Otulana, M.D.

Non-Executive Director

Tunde is currently the Chief Medical Officer of Veloxis Pharmaceuticals in North Carolina, USA since August 2020. Prior to Veloxis he was Senior Vice President and Chief Medical Officer at Mallinckrodt Pharmaceuticals. His career, which spans about 30 years in industry, government and academia, includes leadership roles at Boehringer Ingelheim Pharmaceutical Inc. and the US Food and Drug Administration (“FDA”). Tunde is a physician trained in Pulmonary and Critical Care Medicine.

Beth Alley

Vice President, Regulatory Affairs

Beth Alley has over 20 years of experience within the biopharmaceutical industry in regulatory affairs, commercial strategy, and medical writing throughout all phases of drug development. Her primary areas of focus have been in development of biologics for treatment of autoimmune, inflammatory, and infectious diseases.

Glen Giovanetti

Non-Executive Director

Glen Giovanetti has more than 35 years of experience in strategy and operational leadership in the life science industry as well as in financial governance, risk and reporting as EY’s Global Biotechnology Sector Leader and Life Sciences Sector Leader. He currently serves on the Board of Directors of Life Science Cares, Teon Therapeutics and XW Pharma.

Marla S. Persky

Non-Executive Director

Marla S. Persky currently serves as the chief executive officer and president of WOMN LLC. She has more than 25 years of international senior business and legal experience in the pharmaceutical industry having held numerous business and legal positions at Boehringer Ingelheim and Baxter International. She currently serves on the Boards of Directors of Xeris Pharmaceuticals, YGEIA Consulting Group, Primary Stages, World Neighbors and A Better Chance in Ridgefield.

Dora Rau

Senior Vice President, Quality

Dora Rau brings 25 years of experience in development and commercial operations for drugs, biologics, devices and combination products to the team. She has held numerous executive-level quality positions, with expertise in building quality systems and in leading teams to attain successful regulatory authority inspection outcomes and product approvals.

Jonathan Gold

Chief Financial Officer

Over the last 25 years, Jonathan Gold has been an institutional venture capitalist, a public fund manager, a founder, an operating executive, and a board member for companies across sectors including life sciences. In those roles, he was active in the development, financing and mergers and acquisitions for numerous public and private companies.

Team Members

Michael Albisser

Non-Executive Director​

Michael is a partner of Metellus, a Zurich and London-based venture capital firm investing in technology and life sciences with ground-breaking potential. Having more than 25 years of experience in the finance area he is responsible for finance, tax, and deal structures. He serves on the board of various venture-backed companies.

Dr. Isaac Cheng, m.d.

Non-Executive Director

Dr. Isaac Cheng is currently an investment professional at Morningside, a venture capital and private equity institution based in Boston USA, and Shanghai China. Dr. Cheng focuses primarily on biopharmaceutical and healthcare investments. He has served on numerous public and private company boards.

Peter Greenleaf

Non-Executive Director

Peter Greenleaf currently serves as the chief executive officer (CEO) and member of the Board of Directors of Aurinia, (NASDAQ: AUPH / TSX: AUP), an autoimmune therapeutics company. He has held several other CEO and chairman roles. He is also currently a member of the Board of Directors of Antares Pharmaceuticals, Inc. (NASDAQ: ATRS) and Chairman of the Board of Directors of Biodelivery Sciences International, Inc. (NASDAQ: BDSI).

Marylyn Rigby

SVP of Marketing and Investor Relations

Marylyn Rigby is an experienced pharmaceutical, biotech, and drug delivery professional. In addition to her expertise in marketing, public and investor relations, she has a successful track record with business development, licensing, public and private equity financing, strategy and other key corporate functions.

Nancy Vinh

SVP of Clinical Operations

Nancy Vinh brings over 20 years of experience in managing early and late phase, international clinical trials for drugs, biologics, cell therapy and combination products across a wide range of therapeutic areas to the team. She has served as head of clinical operations and led registrational and label expansion trials execution.

Team Members

Dr. Clare Burgess

Chief Development Officer

Dr. Clare Burgess has 24 years of experience in clinical drug development as a pharmacologist and has worked across a wide range of therapeutic areas within the pharmaceutical industry. She has held multiple leadership roles and has led multidisciplinary teams across the world.

Jeff Myers, m.d., ph.d

Chief Medical Officer

Jeff Myers, M.D., Ph.D., has 20 years of experience in medical affairs, regulatory and clinical development within the biopharmaceutical industry, with focuses on cardiovascular, pulmonary, oncology, and inflammatory diseases.

Before entering the industry, he practiced as a congenital cardiac surgeon and served as the chief of pediatric cardiac surgery at Massachusetts General Hospital and as Associate Professor of Surgery at Harvard Medical School.

Team Members

Dr. Roly Foulkes

Chief Scientific Officer

A true drug discoverer, Dr. Roly Foulkes has 25 years of experience building and delivering innovative therapeutic portfolios within the immunology and inflammatory disease space. He has a strong record advising small and medium sized immunology biopharma companies in developing competitive therapeutic strategies and bringing new innovative molecules to the clinic.

Team Members

Jones w (woody) Bryan, ph.d.

President & Chief Executive Officer

Jones (Woody) Bryan, Ph.D., brings almost 30 years of experience in the healthcare industry to the team, having led successful business development operations in both private and public pharma and biotech companies.

Team Members

Jonathan Rigby, mba

Group Chief Executive Officer

As employee #1 of Revolo Biotherapeutics in the US, Jonathan Rigby has led the company through substantial and rapid growth. He brings three decades of experience creating value and opportunities for companies in the pharmaceutical, biotech and drug delivery technology industry.

Team Members